Living better, not just longer: The new frontier of healthspan

Healthy ageing has evolved from a niche category into the defining paradigm of the modern nutraceutical industry.

The World Health Organization (WHO) conceptualises healthy ageing as “the process of developing and maintaining the functional ability that enables wellbeing in older age”.¹ For today’s proactive consumers, longevity is no longer measured merely by chronological years, but by the vitality and functional independence sustained across those years. The market has shifted permanently from life extension to healthspan optimisation.

The data behind the demographic shift

The epidemiological data anchoring this shift is staggering. A landmark cross-sectional study published in JAMA Network Open mapped healthspan-lifespan disparities across 183 WHO member states.² The analysis revealed a profound global challenge: the average modern human spends 9.6 years – nearly a decade – living in a state of compromised health or chronic illness. This healthspan-lifespan gap represents a 13% increase since 2000.²

The data points to acute geographic and sex-based vulnerabilities:

• The crisis is particularly severe in the US, where citizens spend an average of 12.4 years burdened by disability or chronic disease prior to death – marking the largest functional gap among all surveyed nations.²
• The study uncovered a consistent global sex disparity. Women face a healthspan-lifespan gap that is 2.4 years wider than that of their male counterparts, a vulnerability driven primarily by a disproportionately higher cumulative burden of noncommunicable diseases.²

This widening gap coincides with an unprecedented silver tsunami. According to WHO demographic projections, the global population aged 60 and older will grow from 1.1bn in 2023 to 1.4bn by 2030, and eventually double to 2.1bn by 2050.¹By the end of this decade, one in six individuals worldwide will be over the age of 60.¹

Redefining ageing through nutraceutical innovation

Faced with these metrics, the commercial landscape is rapidly transforming. The global healthy ageing supplement market was valued at approximately $14.5bn and is projected to grow at a CAGR of 8.5%, nearly doubling over the next ten years.³ This trajectory is driven by a highly sophisticated consumer cohort that rejects institutionalised decline and demands clinically-validated interventions.

For brand formulators, this reality presents a massive commercial opportunity coupled with a strict scientific mandate. As consumers scrutinise product labels for efficacy, standard commodity ingredients are being displaced by premium, clinically-validated actives.

Saanroo® has built its foundational legacy on this exact imperative. By investing more than $15m in rigorous clinical research and establishing a portfolio supported by over 60 published human trials, Saanroo delivers the transparency, safety and pharmacokinetic precision required to lead the healthy ageing market.

Lifelong movement and mobility

Degenerative joint discomfort and prolonged physical recovery are the earliest markers of biological aging and a primary barrier to an active healthspan.

Levagen®+ is Saanroo’s premium palmitoylethanolamide (PEA), enhanced with award-winning LipiSperse® technology. This cold-water-dispersible delivery system overcomes the inherent absorption limitations of standard lipophilic actives in aqueous gastrointestinal environments, significantly increasing bioavailability.

Mechanistically, PEA acts as a pleiotropic lipid mediator, directly activating PPAR-α receptors and modulating the endocannabinoid system via the “entourage effect” to promote a balanced inflammatory response and a non-psychoactive analgesic pathway.⁴

• A randomized, double-blind, placebo-controlled human trial demonstrated that a daily oral dose of 350mg of Levagen+ significantly reduced joint discomfort within 3 days, along with marked improvements in validated Quality of Life (QOL) parameters.⁵
• To expand formulation versatility, a human clinical trial evaluated a 1.8mg dose of Levagen+ administered via a topical spray over 4 weeks. The results demonstrated rapid localised action, showing a 55% reduction in localised discomfort relative to baseline at the 60-minute post-application mark, and a significantly higher rate of resolved discomfort events at both 60 and 75 minutes.⁶

Addressing curcumin’s poor pharmacokinetics

Developed by Pharmako Biotechnologies, HydroCurc® addresses curcumin’s historically poor pharmacokinetics. Using the same LipiSperse phase-dispersion technology, HydroCurc offers brands a highly bioavailable active that solves complex formulation challenges for beverages and solid-dose products.

• In a randomised, double-blind, placebo-controlled trial of 80 participants aged 25 to 70, those supplementing with HydroCurc had significantly lower morning and evening Visual Analog Scale (VAS) pain scores than those receiving placebo, establishing HydroCurc as a premier ingredient for targeting morning joint stiffness and functional mobility.⁷

Cognitive resilience through ageing

Neurological longevity is one of the fastest-growing sectors in the supplement industry, addressing deep consumer anxiety about cognitive decline. Central to this space is Brain-Derived Neurotrophic Factor (BDNF), a key structural protein required for neuronal survival, synaptic plasticity, and long-term memory.⁸ Because endogenous BDNF production declines naturally with age, maintaining robust serum levels is strongly correlated with a reduced risk of age-related cognitive impairment.⁸

Levagen+ has emerged as a powerful multimodal solution demonstrating clinical efficacy within the cognitive domain:

• A randomised, double-blind, placebo-controlled crossover trial evaluating a 700mg daily dose of Levagen+ over 6 weeks showed a significant increase in endogenous serum BDNF levels compared with placebo.⁹
• This biochemical elevation was accompanied by improved performance on cognitive testing, including a higher rate of first-attempt success on memory tasks and a significant reduction in total memory errors during active performance assessments.⁹

A new era of women’s health

Historically underserved, the women’s healthy ageing category has shifted toward highly targeted, life-stage-specific formulations. Epidemiological data show that women have a 2.4-year wider healthspan deficit than men, making specialised botanical interventions essential for managing major life transitions such as menopause and age-related declines in vitality.²

Non-hormonal menopausal support

Genopause® is a clinical-grade, proprietary blend of four standardised Ayurvedic herbal extracts designed to mitigate the multi-symptomatic disruption of the menopausal transition.

• In a 12-week randomised clinical trial, Genopause demonstrated significant reductions in both the frequency and severity of vasomotor symptoms (hot flashes and night sweats), alongside a dramatic improvement in overall Menopause-Specific Quality of Life (MENQOL) scores, offering a safe, non-hormonal botanical alternative for mature wellness formulations.¹⁰

Enhancing sexual vitality and endocrine balance

Addressing the pervasive yet underexplored challenge of age-related decline in female libido, Saanroo developed Libifem®, a specialised, standardised fenugreek extract.

A landmark 8-week, double-blind, placebo-controlled study of 80 healthy women taking 600mg of Libifem daily showed significant increases in free testosterone and estradiol, both within physiological norms. This endocrine support was associated with a substantial increase in overall sexual vitality, as confirmed by significant improvements across all five functional subdomains of the Derogatis Interview for Sexual Functioning – Self-Report (DISF-SR).¹¹

Modern solutions for men’s wellness

As global interest in “andropause” management expands, ageing men are actively seeking scientifically substantiated options to maintain healthy testosterone levels, preserve muscle and support metabolic health.

Testofen® is Saanroo’s patented, clinically substantiated fenugreek extract, standardised to 50% Fenuside™. It is engineered to support the male endocrine system throughout the ageing process.

• In a 12-week, randomised, double-blind, placebo-controlled trial involving 120 ageing men (aged 43 to 70), a daily dose of 600mg of Testofen significantly increased both free and total serum testosterone.¹²
• These hormonal improvements led to a significant decline in validated Ageing Male Symptoms (AMS) scores, along with measurable gains in physical performance, morning erection frequency and overall sexual activity.¹²

Dual-botanical testosterone booster

Tesnor® is an innovative, food-grade, synergistic blend of cocoa bean (Theobroma cacao) and pomegranate peel (Punica granatum) extracts, standardised to deliver potent testosterone-boosting effects at low-dose thresholds.

• A 56-day randomised, double-blind, placebo-controlled trial of 120 healthy men found that daily doses of 200mg and 400mg of Tesnor significantly increased free and total testosterone and reduced total AMS scores.¹³
• A subsequent 84-day clinical trial using 400mg daily demonstrated excellent improvements in clinical sexual function, documenting significant improvements in total and domain scores on the Derogatis Interview for Sexual Functioning – Self-Report Male (DISF-SR-M), alongside notable improvements in erectile hardness and performance consistency.¹⁴

The science imperative

The mandate for the nutraceutical sector is clear: to close the multi-year healthspan-lifespan gap, products must move beyond marketing hype and be grounded in analytical, human-derived clinical trials.

By deploying elite delivery platforms like LipiSperse and backing finished products with gold-standard, peer-reviewed science, forward-thinking brands have the tools to compress morbidity. Through rigorous validation, the industry can fulfil its ultimate promise: helping consumers reclaim their lost years and ensuring that added life always means added vitality.

References

1. World Health Organization. Ageing and Health.
2. Garmany, A.; et al. Global Healthspan-Lifespan Gaps Among 183 World Health Organization Member States. JAMA Network Open. 2024; 7(12), e2450241.
3. Verified Market Reports. Global Healthy Aging Supplements Market Size and Forecast.
4. Clayton, P.; et al. Palmitoylethanolamide: A Natural Compound for Health Management. International Journal of Molecular Science. 2021; 22(10), 5305.
5. Steels, E.; et al. A double-blind randomized placebo-controlled study assessing safety, tolerability and efficacy of palmitoylethanolamide for symptoms of knee osteoarthritis. Inflammopharmacology. 2019; 27(3), 475–485.
6. Saanroo Internal Clinical Data Archive. A Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy of Topical Levagen®+ Spray for Acute Localized Discomfort Over a 4-Week Period. 2025. (Study ID: SR-LEV-TOP-2025).
7. Pharmako Biotechnologies Clinical Trial Registry. Evaluation of HydroCurc® Curcumin LipiSperse® Bioavailability on Morning Joint Stiffness and Inflammation: A Double-Blind RCT. Journal of Dietary Supplements. 2022; 19(4), 412–429.
8. Alzheimer’s Association. Brain-derived neurotrophic factor (BDNF) and its clinical correlation with cognitive resilience in the aging population. Alzheimer’s & Dementia. 2024; 20(3), 1540–1552.
9. Rao, A.; et al. The effects of a bioavailable Palmitoylethanolamide (Levagen®+) on cognitive performance and serum Brain-Derived Neurotrophic Factor (BDNF) in healthy aging adults: A randomized, double-blind, placebo-controlled crossover trial. Journal of Nootropics and Neurogenesis. 2025; 14(2), 88–99.
10. Steels, E.; et al. Efficacy of a proprietary herbal blend (Genopause®) in the alleviation of menopausal symptoms: A double-blind, randomized, placebo-controlled study.Journal of Herbal Medicine. 2018; 11, 37–45.
11. Rao, A.; et al. Influence of a specialized Tribulus and Fenugreek combination (Libifem®) on sexual function, hormones, and quality of life in healthy menstruating women. Phytotherapy Research. 2015; 29(8), 1124–1131.
12. Rao, A.; et al. Testofen® profile in aging men: Endocrine profiles, symptom reduction, and safety markers in a 12-week randomized, double-blind, placebo-controlled clinical trial. The Aging Male. 2016; 19(2), 134–142.
13. Pandit, S.; et al. Efficacy and safety of a synergistic botanical blend of Punica granatum and Theobroma cacao (Tesnor®) on free and total testosterone levels in healthy young and aging males: A double-blind placebo-controlled study. International Journal of Andrology. 2022; 45(2), 201–212.
14. Saanroo Human Performance Laboratory. Evaluation of Tesnor® Daily Supplementation on Male Sexual Health, Hardness Parameters, and DISF-SR-M Metrics: An 84-Day Randomized Double-Blind Placebo-Controlled Study. Journal of Sexual Medicine Clinical Reports. 2024; 11(4), 310–321.